Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 330

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 13
Chunk 330
---
10,433,848  $11,399,793              LIABILITIES AND STOCKHOLDERS’ EQUITY            CURRENT LIABILITIES            Trade payables (including $Nil and $21,953 of trade payables from related parties for December 31, 2024 and 2023 respectively)  8   1,503,326   1,402,180 Other payables and accrued liabilities      284,108   180,912 Current portion of operating lease liabilities  5   50,816   34,632 Advance payment from customer      95,879   - Amount owing to directors      17,174   13,199 Total current liabilities      1,951,303   1,630,923              NON-CURRENT LIABILITIES            Non-current portion of operating lease liabilities  5   159,741   98,763 Deferred tax liabilities  4   -   12,255 Total non-current liabilities      159,741   111,018 TOTAL LIABILITIES     $2,111,044  $1,741,941 

See accompanying notes to the consolidated financial statements.

 F-4Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

BIONEXUS GENE LAB CORP. 

CONSOLIDATED BALANCE SHEETS 

AS OF DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

    As of     December 31,  December 31,   Note  2024  2023 STOCKHOLDERS’ EQUITY         As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 17,967,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2023, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value 30,000,000 shares authorized and no shares outstanding (on a post-re